Trending...
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- New Bethany, Provident Bank, Jaindl Farms and Lehigh Valley IronPigs Unite for Turkey Drive
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
CENTER VALLEY, Pa. and TOKYO, Dec. 30, 2020 /PRNewswire/ -- Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, following the definitive agreement the two companies signed December 4, 2020. With this acquisition by Olympus subsidiary Olympus Corporation of the Americas (OCA), Olympus gains VMT's global sales network, marketing, manufacturing, R&D, and other functions to expand the Olympus respiratory product portfolio.
Lung cancer is the leading cause of cancer-related deaths globally.1 With increased awareness and more lung cancer screenings using low-dose computed tomography (CT), the need for definitive diagnosis of lesions in the peripheral regions of the lungs by tissue biopsy is expected to increase. VMT's SPiN Thoracic Navigation System® and related devices are specifically designed to help physicians navigate to, localize, and sample peripheral pulmonary lesions. Together with the existing Olympus respiratory portfolio that includes radial endobronchial ultrasound (EBUS) and thin bronchoscopes, VMT's navigational system and related devices provide a powerful combination of imaging, access and precision for pulmonologists seeking to diagnose and determine the stage of a patient's lung cancer.
More on The PennZone
"We are very excited about the synergies this acquisition creates. With the deal now closed, as one company we are able to combine Olympus' expertise and clinical history in minimally invasive technology with the innovation in navigation systems of Veran Medical Technology to improve workflow and patient care in lung cancer," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is committed to providing the medical community with the best tools possible to use in their fight against cancer. With the advent of EBUS-guided transbronchial needle aspiration (EBUS-TBNA) in 2004, Olympus brought patients the benefit of more accurate diagnosis and staging, to improve patient outcomes and care. We are thrilled to be at the forefront of development in this rapidly evolving area of respiratory care."
The acquisition will provide immediate incremental revenue and an experienced sales team within the U.S. market. VMT's advanced and proven navigation technology, together with Olympus' respiratory portfolio, strengthens and enhances Olympus' global position as a medical technology innovator.
As part of its current Corporate Strategy, Olympus vowed to "focus and scale" its Therapeutic solutions Division (TSD). To accelerate the process and provide greater agility, Olympus made OCA the TSD headquarters, recognizing the significant growth opportunities in North America. Olympus also identified three core medical fields to prioritize and has since focused on gastroenterological endotherapy devices, urological devices, and respiratory devices. The VMT acquisition is centered on respiratory devices and will position Olympus as a leader in this field.
More on The PennZone
For additional information, please refer to our corporate disclosure, "Notice regarding acquisition of Veran Medical Technologies, Inc. in the United States."
(available at: https://www.olympus-global.com/news/ir/2020/)
1 WHO data: https://www.who.int/news-room/fact-sheets/detail/cancer
About Olympus' Therapeutic Solutions Division
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.
SOURCE Olympus
Related Links
http://www.olympus.com/
Lung cancer is the leading cause of cancer-related deaths globally.1 With increased awareness and more lung cancer screenings using low-dose computed tomography (CT), the need for definitive diagnosis of lesions in the peripheral regions of the lungs by tissue biopsy is expected to increase. VMT's SPiN Thoracic Navigation System® and related devices are specifically designed to help physicians navigate to, localize, and sample peripheral pulmonary lesions. Together with the existing Olympus respiratory portfolio that includes radial endobronchial ultrasound (EBUS) and thin bronchoscopes, VMT's navigational system and related devices provide a powerful combination of imaging, access and precision for pulmonologists seeking to diagnose and determine the stage of a patient's lung cancer.
More on The PennZone
- 6,238 executives took new roles at US nonprofits from June to October 2026
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
- LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
- Woodside Village Joins Corner Property Management Following CMP Acquisition
- 20-Year Crash Cost of Signalized RC3 Cloverleaf Could Exceed $25 Million
"We are very excited about the synergies this acquisition creates. With the deal now closed, as one company we are able to combine Olympus' expertise and clinical history in minimally invasive technology with the innovation in navigation systems of Veran Medical Technology to improve workflow and patient care in lung cancer," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is committed to providing the medical community with the best tools possible to use in their fight against cancer. With the advent of EBUS-guided transbronchial needle aspiration (EBUS-TBNA) in 2004, Olympus brought patients the benefit of more accurate diagnosis and staging, to improve patient outcomes and care. We are thrilled to be at the forefront of development in this rapidly evolving area of respiratory care."
The acquisition will provide immediate incremental revenue and an experienced sales team within the U.S. market. VMT's advanced and proven navigation technology, together with Olympus' respiratory portfolio, strengthens and enhances Olympus' global position as a medical technology innovator.
As part of its current Corporate Strategy, Olympus vowed to "focus and scale" its Therapeutic solutions Division (TSD). To accelerate the process and provide greater agility, Olympus made OCA the TSD headquarters, recognizing the significant growth opportunities in North America. Olympus also identified three core medical fields to prioritize and has since focused on gastroenterological endotherapy devices, urological devices, and respiratory devices. The VMT acquisition is centered on respiratory devices and will position Olympus as a leader in this field.
More on The PennZone
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
- Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
- BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
- Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
- Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
For additional information, please refer to our corporate disclosure, "Notice regarding acquisition of Veran Medical Technologies, Inc. in the United States."
(available at: https://www.olympus-global.com/news/ir/2020/)
1 WHO data: https://www.who.int/news-room/fact-sheets/detail/cancer
About Olympus' Therapeutic Solutions Division
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.
SOURCE Olympus
Related Links
http://www.olympus.com/
Filed Under: Business
0 Comments
Latest on The PennZone
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
- Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
- Kitchen Table Economics: An Invitation to Think Differently
- New Bethany, Provident Bank, Jaindl Farms and Lehigh Valley IronPigs Unite for Turkey Drive
- Grace Montessori School Awarded $56,180 to Support Scholarships for 15 Students
- Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
- CB Stuffer Announces Private Sale to Secure Future of Brand Growth
- Brother Marcus Celebrates 400th Episode of The Elements of Inspiration Podcast
- USA Dental Edge Unveils Dental Intelligence
- The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
- Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
- Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- An AI Plays Kenshi Entirely by Itself, Live 23 Hours a Day, With an AI Host and Chat Voting
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
- Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
- Meals on Wheels of the Greater Lehigh Valley Raises Over $50,000 to Help Feed Local Seniors
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
